TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
Recruiting
N/A
Interventional Study
Hepatocellular Carcinoma Recurrent
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 22 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 198 (estimated)
- Sponsor
- Barbara Ann Karmanos Cancer Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are:
* will the TheraBionic P1 device affect overall survival in advance HCC
* the long term safety and tolerability of the TheraBionic P1 device
* assessment …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with advanced hepatocellular carcinoma (HCC) (defined as a liver tumor not eligible for local therapies given the extent of disease or a livor tumor that recurred after local therapy)
* Patients who have failed at least two lines of therapy\* or who are no longer elig…
Contacts